Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 9:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 920 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hepatitis C Virus (HCV) Clear all
Completed Phase 2 Interventional Results available

A Multiple Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Genotype 1 Infected Subjects

NCT00663208
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Daclatasvir, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 60 Years
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
7
States / cities
Anaheim, California • Cypress, California • New Haven, Connecticut + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Oct 17, 2026, 9:51 AM EDT
Completed Phase 2 Interventional Results available

Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection

NCT01132313
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
BI 207127, BI 201335, Ribavirin, BI 207217
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
12
States / cities
La Jolla, California • San Diego, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2016 · Synced Oct 17, 2026, 9:51 AM EDT
Completed Phase 2 Interventional

A Study of Faldaprevir, Ribavirin and TD-6450 in Participants With Genotype 4 Hepatitis C Virus Infection

NCT02593162
View directory record Official record
Conditions
Hepatitis C Viral Infection, Chronic Hepatitis C, Hepatitis C (HCV), Hepatitis C Genotype 4
Interventions
Faldaprevir, TD-6450, Ribavirin
Drug
Lead sponsor
Trek Therapeutics, PBC
Industry
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Coronado, California
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Oct 17, 2026, 9:51 AM EDT
Completed Not applicable Interventional

Increasing HCV Linkage to Care Among People Who Inject Drugs

NCT04741750
View directory record Official record
Conditions
Hepatitis C
Interventions
Simplified HCV care within a mobile medical unit
Other
Lead sponsor
Family Health Centers of San Diego
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Oct 17, 2026, 9:51 AM EDT
Completed Phase 2 Interventional

A Study of Albuferon With Ribavirin in Interferon Treatment Experienced Subjects With Chronic Hepatitis C

NCT00097435
View directory record Official record
Conditions
Hepatitis C
Interventions
Albuferon, Ribavirin
Drug
Lead sponsor
Human Genome Sciences Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
8
States / cities
Phoenix, Arizona • Gainesville, Florida • Jacksonville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2013 · Synced Oct 17, 2026, 9:51 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Sulfation of Bile Acids as a Biomarker for Hepatobiliary Diseases

NCT01200082
View directory record Official record
Conditions
Hepatobiliary Diseases
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 65 Years
Enrollment
430 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2022
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Oct 17, 2026, 9:51 AM EDT
Completed Phase 2 Interventional Results available

A Follow-up Assessment of Resistance to ABT-333 in Hepatitis C Virus (HCV)-Infected Subjects Who Have Received ABT-333 in ABT-333 Studies

NCT00726882
View directory record Official record
Conditions
HCV Infection
Interventions
Blood sample collection only, ABT-333
Procedure · Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
6
States / cities
Anaheim, California • Los Angeles, California • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2015 · Synced Oct 17, 2026, 9:51 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of the Therapeutic Vaccine GI-5005 Combined With Pegylated Interferon Plus Ribavirin Standard of Care Therapy Versus Standard of Care Alone in Patients With Genotype 1 Chronic Hepatitis C Infection

NCT00606086
View directory record Official record
Conditions
Genotype 1 Chronic Hepatitis C
Interventions
GI-5005, Pegylated Interferon and Ribavirin
Drug
Lead sponsor
GlobeImmune
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
25
States / cities
Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2014 · Synced Oct 17, 2026, 9:51 AM EDT
Withdrawn Phase 4 Interventional

A Single-arm Evaluation of the Effect of HCV Treatment on Cardiovascular Disease Risk

NCT03585101
View directory record Official record
Conditions
Hepatitis C
Interventions
Elbasvir/grazoprevir
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Oct 17, 2026, 9:51 AM EDT
Completed Phase 4 Interventional Results available

The SIM-SOF Trial for Hepatitis C

NCT02168361
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Pegylated Interferon alfa-2b, Simeprevir, Ribavirin, Sofosbuvir
Drug
Lead sponsor
Center For Hepatitis C, Atlanta, GA
Other
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Oct 17, 2026, 9:51 AM EDT
Completed Phase 4 Interventional Results available

Effects of Ledipasvir/Sofosbuvir on the Pharmacokinetics and Renal Safety of Tenofovir Alafenamide (TAF)

NCT03126370
View directory record Official record
Conditions
Hepatitis C, HIV Coinfection
Interventions
TDF with a boosted protease inhibitor, TAF with a boosted protease inhibitor, TAF with a boosted protease inhibitor and LDV/SOF
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Oct 17, 2026, 9:51 AM EDT
Completed Phase 3 Interventional Results available

SOF (Sovaldi®) +RBV for 16 or 24 Weeks and SOF+RBV+Peg-IFN for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection

NCT01962441
View directory record Official record
Conditions
Hepatitis C
Interventions
SOF, RBV, Peg-IFN
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
23
States / cities
Riverside, California • San Diego, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Oct 17, 2026, 9:51 AM EDT
Completed Phase 3 Interventional Results available

Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects

NCT03092375
View directory record Official record
Conditions
Hepatitis C, HCV
Interventions
Glecaprevir/Pibrentasvir (G/P) 300mg/120mg, Ribavirin 200Mg Tablet
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
31
States / cities
Palo Alto, California • San Francisco, California • Washington D.C., District of Columbia + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Oct 17, 2026, 9:51 AM EDT
Completed Phase 1 Interventional

Study of Hepatitis C Treatment During Pregnancy

NCT02683005
View directory record Official record
Conditions
Hepatitis C, Pregnancy
Interventions
ledipasvir/sofosbuvir
Drug
Lead sponsor
Catherine Chappell
Other
Eligibility
18 Years to 39 Years · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 17, 2026, 9:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of the ABT-333 Tablet

NCT00909636
View directory record Official record
Conditions
HCV Infection
Interventions
ABT-333, Placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Waukegan, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 13, 2010 · Synced Oct 17, 2026, 9:51 AM EDT
Terminated Phase 4 Interventional Results available

Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Lung Transplant

NCT03625687
View directory record Official record
Conditions
Respiratory Failure, Hepatitis C
Interventions
Clinically prescribed direct acting antiviral (Mavyret or Epclusa) HCV treatment for 8 weeks
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 25, 2023 · Synced Oct 17, 2026, 9:51 AM EDT
Completed No phase listed Observational

A Study to Examine Patient Characteristics, Health Care Management and Health Outcomes of Hepatitis C Virus (HCV) Patients Treated With Simeprevir

NCT02103699
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
No intervention
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
32
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2016 · Synced Oct 17, 2026, 9:51 AM EDT
Recruiting Not applicable Interventional

Hepatitis C Tracker Study

NCT06870019
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
GPS tracker device
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Alhambra, California • Ventura, California
Source: ClinicalTrials.gov public record
Updated Aug 29, 2025 · Synced Oct 17, 2026, 9:51 AM EDT
Completed No phase listed Observational

Transplant-Related Accelerated Progression of Hepatitis C

NCT00368225
View directory record Official record
Conditions
Hepatitis C, Cirrhosis
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland • Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 17, 2026, 9:51 AM EDT
Completed Phase 3 Interventional Results available

Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease

NCT00529568
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
eltrombopag, placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
59
States / cities
Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 49 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2013 · Synced Oct 17, 2026, 9:51 AM EDT
Completed Phase 1 Interventional

An Open Label Non-Randomized Dose Escalating Trial to Assess Safety and Tolerability of Alb-Interferon Alfa 2b Every Two Weeks With Ribavirin Among HIV/HCV Coinfected Individuals

NCT00489385
View directory record Official record
Conditions
HIV Infections, HCV
Interventions
Albinterferon, Ribavirin, Albuferon
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 17, 2026, 9:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Interaction of Alcohol and Highly Active Antiretroviral Therapy (HAART) in HIV/AIDS and HIV/AIDS With Hepatitis C Virus (HCV) Co-Infection

NCT00879047
View directory record Official record
Conditions
HIV Infections, Hepatitis C
Interventions
Alcohol, Alcohol placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 6, 2014 · Synced Oct 17, 2026, 9:51 AM EDT
Not listed Not applicable Interventional

The Staying Safe Intervention

NCT03418636
View directory record Official record
Conditions
Hepatitis C, Opioid Use
Interventions
Staying Safe (Ssafe), Healthy Living
Behavioral
Lead sponsor
National Development and Research Institutes, Inc.
Other
Eligibility
18 Years to 29 Years
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Oct 17, 2026, 9:51 AM EDT
Completed Not applicable Interventional

Intervention to Improve HCV Treatment Uptake and Adherence in HIV/HCV Coinfection

NCT02294136
View directory record Official record
Conditions
HIV, Hepatitis C, Co-Infection
Interventions
Prep-C, Educational Control
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
21 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 2, 2017 · Synced Oct 17, 2026, 9:51 AM EDT